Navi Lifesciences
NavigatingAdvancedVentures &Innovation

Where Science Meets Strategy. Where Innovation Finds Its Market.

Navi Lifesciences is a founder-led advisory firm in Abu Dhabi. We help pharma, biotech, health systems and AI companies turn science into market-ready decisions in the GCC and beyond: what to develop, where to compete, whom to partner with, and how to win.

Discuss Your Mandate Explore Capabilities

www.navilifesciences.com  ·  vivek.singh@navilifesciences.com  ·  +971 52 107 9931

15+
Years across biopharma BD, CI and market strategy
$150M
20-year CAR-T out-licensing deal led across three markets
$700M
Savings potential identified through a CI-led development plan
4
Regions of execution: GCC, Africa, APAC and LATAM
Three Capabilities · One Partner

Science-Led Strategy, Data & AI for Life Sciences

Every engagement starts with a decision our client has to make and ends with a recommendation they can act on. Three integrated capabilities, one accountable senior partner.

Capability 01

Competitive Intelligence & BD Advisory

Decisions, not just data.

  • Landscape, pipeline and conference intelligence
  • BD, licensing and partnering strategy, from scouting to deal
  • GTM, market access and new-market entry, worldwide
  • Asset scouting and scientific & commercial due diligence
Explore advisory →
Capability 02

Clinical Trials Intelligence Platform

Decision-grade trial analytics, with Baltcore.

  • One live view of every study, site, subject and dirham
  • Early alerts on enrolment, quality, IP and budget risk
  • Role-based views for CXOs, PIs, CRAs, BD and sponsors
  • Built on the CTMS, EDC, eTMF and finance data you already hold
See the platform →
Capability 03

AI × Life Sciences Partnerships

Problems in, pilots out.

  • Validated life sciences use cases, each with a named buyer
  • Domain design with GxP and data-residency guardrails
  • Joint go-to-market into pharma, payers and providers
  • Six pilot-ready use cases, from safety AI to trial feasibility
View AI use cases →
Why the GCC, Why Now

The Region's Life Sciences Sector Is Scaling, and the Policy Is Behind It

From Masdar City, we sit inside one of the world's fastest-moving life sciences ecosystems. We help global innovators enter it and regional players compete beyond it.

$49B
GCC pharma market by 2033, up from $23.7B in 2024
$25.6B
GDP target for Abu Dhabi's HELM life sciences cluster by 2045
800K+
Emirati genomes sequenced: a national precision-medicine asset
~25%
Annual growth of AI in GCC healthcare through 2035

Sources: IMARC Group, GCC Pharmaceuticals Market (2025); Abu Dhabi Media Office, HELM cluster launch (Apr 2025); The National, Emirati Genome Programme (Apr 2025); Market Research Future, GCC Healthcare AI (2024–35).

Our Approach

Consulting Rigour. Scientific Depth. Commercial Insight.

We work like a strategy consultancy and think like scientists. Every question is framed as a decision, every hypothesis is tested against primary and secondary evidence, and every deliverable ends with a clear "so what".

  1. Which assets, indications and markets deserve our capital?
  2. Who are the right partners, and what is the deal worth?
  3. How do we launch, price and secure patient access in each target market?
  4. Where can AI and data create measurable value, and for whom?
Illustrative competitive landscape: solid-tumour pipeline assets by mechanism of action and development phase, highlighting a Phase III white-space gap
Therapeutic Focus

Deep Expertise Where Science Is Moving Fastest

Cell & Gene Therapy

CAR-T · TCR-T · TIL · gene editing · viral vectors

Immuno-Oncology

Checkpoint inhibitors · bispecifics · ADCs

Regenerative Medicine

Stem cells · iPSC · exosomes · tissue engineering

Infectious Disease & Vaccines

Vaccines · antivirals · rare genetic disorders

Dr. Vivek Vikram Singh, Founder and Managing Director
Dr. Vivek Vikram Singh, PhDFounder & Managing Director
Founder-Led Advisory

Scientist by Training. Strategist by Practice.

Every Navi engagement is led personally by Dr. Vivek Vikram Singh. He brings 15+ years across biopharma business development, competitive intelligence and international expansion, built at ImmunoACT, Deallus and WNS on a research career in regenerative and cellular immunology.

$150M

20-year CAR-T out-licensing across South Africa, Morocco and Algeria

20+

Person life sciences CI team led for a Swiss pharma major

Meet the Founder

How We Engage

Engagements Shaped Around the Decision You Need to Make

4–12 weeks

Project-Based Advisory

Landscape studies, use-case design, deal preparation.

3–12 months

Retainer Advisory

Sustained CI monitoring, BD and GTM execution.

Part-time

Fractional Strategy Leadership

A senior life sciences lead embedded in your team.

1–3 days

Workshop & Strategy Sprint

Pre-partnering sprints, board and annual planning.

See engagement models in detail →

Latest Insight · LinkedIn
“A breakthrough therapy is only the beginning.”
Dr. Vivek Vikram Singh
Perspective

From Asset Hunting to Ecosystem Building: The New Playbook for Biopharma Growth

Developing a breakthrough therapy is only the first step. The winners will be those who get innovation to patients through partnerships, scalable manufacturing, market-access strategy and local execution, with cell and gene therapy and the rising influence of the GCC, India and China reshaping the map.

Read the Insight

Let's Navigate Your Next Move

Tell us the decision in front of you. We will come back within one business day.

Start a Conversation +971 52 107 9931